Cargando…

Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review

BACKGROUND: Computed tomography (CT) analysis of body composition has garnered interest as a potential prognostic tool in those with cancer. A range of pre‐defined thresholds currently exist within the literature to define low skeletal muscle mass and density. The aim of the present systematic revie...

Descripción completa

Detalles Bibliográficos
Autores principales: McGovern, Josh, Dolan, Ross D., Horgan, Paul G., Laird, Barry J., McMillan, Donald C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718024/
https://www.ncbi.nlm.nih.gov/pubmed/34664431
http://dx.doi.org/10.1002/jcsm.12831
_version_ 1784624632905596928
author McGovern, Josh
Dolan, Ross D.
Horgan, Paul G.
Laird, Barry J.
McMillan, Donald C.
author_facet McGovern, Josh
Dolan, Ross D.
Horgan, Paul G.
Laird, Barry J.
McMillan, Donald C.
author_sort McGovern, Josh
collection PubMed
description BACKGROUND: Computed tomography (CT) analysis of body composition has garnered interest as a potential prognostic tool in those with cancer. A range of pre‐defined thresholds currently exist within the literature to define low skeletal muscle mass and density. The aim of the present systematic review was to assess the prevalence of low skeletal muscle index (SMI) and density (SMD) within the literature, across a range of common solid tumours. METHODS: A systematic search of PubMed was carried out to identify studies reporting CT analysis of SMI and SMD in patients with colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast, and lung cancer. The type of cancer, whether curative or non‐curative disease, the anthropomorphic parameter studied, threshold used to define low SMI and SMD, and the prevalence of these anthropomorphic measurements within the population were recorded. RESULTS: Of the 160 studies included, 156 reported an assessment of SMI and 35 reported assessment of SMD. The median prevalence of low SMI was 43% (30.1–57.1) and low SMD 49.4% (31.7–58.5) across the entire cohort. There was little variation in the prevalence of low SMI and SMD when studies were divided into curative and non‐curative cohorts—40.7% (27.5–51.3) vs. 48.4% (30.9–60.1) and 37.8% (32.2–52.2) vs. 55.3% (38.5–64.7) respectively. When divided into colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast and lung cancers, similar prevalence of low SMI (46.0% %, 49.8%, 35.7%, 41.1%, 32.3%, 34%, and 49.5%) and low SMD were also observed (52.1%, 54.3%, 71.2%, 56.8%, 55.3%, and 52.6%). This was maintained when studies were stratified into cohorts by threshold used—low SMI (Martin 48.9%, Prado 49.9%, and Others 36.0%) and low SMD (Martin 52.4% and Others 48.6%). CONCLUSIONS: Low SMI and SMD are endemic across a range of cancer types and disease stage, challenging pre‐existing dogma of the determinants of prevalence.
format Online
Article
Text
id pubmed-8718024
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87180242022-01-06 Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review McGovern, Josh Dolan, Ross D. Horgan, Paul G. Laird, Barry J. McMillan, Donald C. J Cachexia Sarcopenia Muscle Reviews BACKGROUND: Computed tomography (CT) analysis of body composition has garnered interest as a potential prognostic tool in those with cancer. A range of pre‐defined thresholds currently exist within the literature to define low skeletal muscle mass and density. The aim of the present systematic review was to assess the prevalence of low skeletal muscle index (SMI) and density (SMD) within the literature, across a range of common solid tumours. METHODS: A systematic search of PubMed was carried out to identify studies reporting CT analysis of SMI and SMD in patients with colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast, and lung cancer. The type of cancer, whether curative or non‐curative disease, the anthropomorphic parameter studied, threshold used to define low SMI and SMD, and the prevalence of these anthropomorphic measurements within the population were recorded. RESULTS: Of the 160 studies included, 156 reported an assessment of SMI and 35 reported assessment of SMD. The median prevalence of low SMI was 43% (30.1–57.1) and low SMD 49.4% (31.7–58.5) across the entire cohort. There was little variation in the prevalence of low SMI and SMD when studies were divided into curative and non‐curative cohorts—40.7% (27.5–51.3) vs. 48.4% (30.9–60.1) and 37.8% (32.2–52.2) vs. 55.3% (38.5–64.7) respectively. When divided into colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast and lung cancers, similar prevalence of low SMI (46.0% %, 49.8%, 35.7%, 41.1%, 32.3%, 34%, and 49.5%) and low SMD were also observed (52.1%, 54.3%, 71.2%, 56.8%, 55.3%, and 52.6%). This was maintained when studies were stratified into cohorts by threshold used—low SMI (Martin 48.9%, Prado 49.9%, and Others 36.0%) and low SMD (Martin 52.4% and Others 48.6%). CONCLUSIONS: Low SMI and SMD are endemic across a range of cancer types and disease stage, challenging pre‐existing dogma of the determinants of prevalence. John Wiley and Sons Inc. 2021-10-18 2021-12 /pmc/articles/PMC8718024/ /pubmed/34664431 http://dx.doi.org/10.1002/jcsm.12831 Text en © 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
McGovern, Josh
Dolan, Ross D.
Horgan, Paul G.
Laird, Barry J.
McMillan, Donald C.
Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review
title Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review
title_full Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review
title_fullStr Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review
title_full_unstemmed Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review
title_short Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review
title_sort computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718024/
https://www.ncbi.nlm.nih.gov/pubmed/34664431
http://dx.doi.org/10.1002/jcsm.12831
work_keys_str_mv AT mcgovernjosh computedtomographydefinedlowskeletalmuscleindexanddensityincancerpatientsobservationsfromasystematicreview
AT dolanrossd computedtomographydefinedlowskeletalmuscleindexanddensityincancerpatientsobservationsfromasystematicreview
AT horganpaulg computedtomographydefinedlowskeletalmuscleindexanddensityincancerpatientsobservationsfromasystematicreview
AT lairdbarryj computedtomographydefinedlowskeletalmuscleindexanddensityincancerpatientsobservationsfromasystematicreview
AT mcmillandonaldc computedtomographydefinedlowskeletalmuscleindexanddensityincancerpatientsobservationsfromasystematicreview